Abstract
Over 90% of individuals with Alzheimer's disease (AD) experience agitation which increase morbidity and mortality and contribute to caregiver burden. There are no FDA-approved treatments for severe agitation in people with advanced dementia. Psychotropic medications used off-label have limited efficacy and risk for adverse effects. Behavioral interventions are not effective in the most severely agitated patients. New management strategies for severe agitation in AD refractory to psychopharmacologic and behavioral interventions are timely and warranted. Preliminary studies provide evidence for the safety and efficacy of acute electroconvulsive therapy (ECT) in reducing agitation in this population. In this session we will describe lessons learned so far in the process of creating a multisite research consortium, designing a single blind, randomized clinical trial of ECT to determine efficacy and safety for severe agitation in advanced AD, applying for NIH grant, navigating regulations at the local, state, and federal level, and overcoming challenges with study implementation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
